Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Akamai Technologies, Inc. (AKAM) Droops On Weak Results, Guidance: Good Time To Buy?

Page 1 of 2

Akamai Technologies, Inc. (NASDAQ:AKAM) reported its second quarter financial results after the close of trading last night, with the results showing that the cloud services provider missed the Street’s expectations on earnings, while also providing soft guidance for the third quarter, which made its investors wary, sending shares down by 7.40% in morning trading. Akamai Technologies, Inc. (NASDAQ:AKAM) reported adjusted EPS of $0.57 on total revenue of $540.7 million. However the Zacks consensus estimate stood at EPS of $0.58 on revenue of $540.1 million. Even though the company reported a slight beat on revenues, the earnings miss coupled with the lower third quarter guidance has prompted the sell-off. The cloud services provider offered third quarter revenue guidance of $543 million – $555 million with an earnings guidance of $0.56 – $0.58 per share. These figures were well below consensus expectations of $565.1 million in revenues with earnings of $0.62 per share. The stock had gained around 15% so far in 2015, with most of the gains coming in the first quarter. But the disappointing third quarter guidance might hit the stock hard over the next few days.


Hedge funds were slightly bullish on Akamai at the start of the year. At the end of the first quarter, a total of 37 of the hedge funds tracked by Insider Monkey were bullish in Akamai Technologies, Inc. (NASDAQ:AKAM), with a total investment of $1.12 billion, an increase of 16% compared to the aggregate holdings of the 36 hedge funds with positions in the company at the end of the fourth quarter. During the January – March period the stock appreciated by around 13%, which indicates that hedge funds did not add very much to their positions, despite the 16% increase in their collective value.

But why do we track hedge fund activity? From one point of view we can argue that hedge funds are consistently underperforming when it comes to net returns over the last three years, when compared to the S&P 500. But that doesn’t mean that we should completely neglect the hedge funds’ activities. There are various reasons behind the low hedge fund returns. Our research indicated that hedge funds’ long positions actually beat the market. In our back-tests covering the 1999-2012 period hedge funds’ top small cap stocks edged the S&P 500 index by double digits annually. The 15 most popular small cap stock picks among hedge funds also bested passive index funds by around 66 percentage points over the 34 month period beginning in September 2012, returning over 123% (read the details here).

Likewise, other research (not our own) has shown insider purchases are also effective piggybacking methods for investors that lead to greater returns. That’s why we believe investors should pay attention to what hedge funds and insiders are buying and keep them apprised of this information. Looking at Akamai Technologies, Inc. (NASDAQ:AKAM) there were no insider purchase of the stock during the first half of this year, but there were a few insider sales. Executive Vice Chairman of the Board, Paul Sagan sold around 170,000 shares, and President of Product and Development, Rick McConnell sold around 33,000 shares so far this year.

Taking this in consideration, let’s review the latest actions surrounding Akamai Technologies, Inc. (NASDAQ:AKAM).

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!